A Phase II/III Study to Evaluate the Efficacy and Safety of BAT4406F Injection in Patients with Neuromyelitis Optica Lineage Disease
Latest Information Update: 04 Nov 2024
At a glance
- Drugs BAT 4406F (Primary)
- Indications Neuromyelitis optica
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Bio-Thera Solutions
Most Recent Events
- 26 Sep 2023 New trial record